当前位置：
X-MOL 学术
›
N. Engl. J. Med.
›
论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2017-11-04 , DOI: 10.1056/nejmoa1710030 Vicente E Torres 1 , Arlene B Chapman 1 , Olivier Devuyst 1 , Ron T Gansevoort 1 , Ronald D Perrone 1 , Gary Koch 1 , John Ouyang 1 , Robert D McQuade 1 , Jaime D Blais 1 , Frank S Czerwiec 1 , Olga Sergeyeva 1 ,
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2017-11-04 , DOI: 10.1056/nejmoa1710030 Vicente E Torres 1 , Arlene B Chapman 1 , Olivier Devuyst 1 , Ron T Gansevoort 1 , Ronald D Perrone 1 , Gary Koch 1 , John Ouyang 1 , Robert D McQuade 1 , Jaime D Blais 1 , Frank S Czerwiec 1 , Olga Sergeyeva 1 ,
Affiliation
|
Tolvaptan resulted in a slower decline than placebo in the estimated GFR over a 1-year period in patients with later-stage ADPKD. (Funded by Otsuka Pharmaceuticals and Otsuka Pharmaceutical Development and Commercialization; REPRISE ClinicalTrials.gov number, NCT02160145.)
中文翻译：
托伐普坦在晚期常染色体显性多囊肾疾病中的应用。
在晚期ADPKD患者中，托伐普坦导致的GFR估计值在1年内的下降速度比安慰剂慢。（由Otsuka Pharmaceuticals和Otsuka Pharmaceutical Development and Commercialization资助； REPRISE ClinicalTrials.gov编号，NCT02160145。）
更新日期：2017-11-16
中文翻译：
托伐普坦在晚期常染色体显性多囊肾疾病中的应用。
在晚期ADPKD患者中，托伐普坦导致的GFR估计值在1年内的下降速度比安慰剂慢。（由Otsuka Pharmaceuticals和Otsuka Pharmaceutical Development and Commercialization资助； REPRISE ClinicalTrials.gov编号，NCT02160145。）
京公网安备 11010802027423号